TickerFacts.

Revolution Medicines, Inc. (RVMD): Net Income

Annual figures by period end, from SEC filings.

-$1.13B
Year ended 2025-12-31
-$1.77B
Trailing 12 months to 2026-06-30
2018-12-31: -$41.79M2019-12-31: -$47.66M2020-12-31: -$108.16M2021-12-31: -$187.09M2022-12-31: -$248.71M2023-12-31: -$436.37M2024-12-31: -$600.09M2025-12-31: -$1.13B-$1.13B
2018-12-31 Net Income (USD) 2025-12-31
Period endedNet IncomeChange YoYSource filing
2025-12-31-$1.13Bn/m2026-02-25, From 2025-01-01
2024-12-31-$600.09Mn/m2026-02-25, From 2024-01-01
2023-12-31-$436.37Mn/m2026-02-25, From 2023-01-01
2022-12-31-$248.71Mn/m2025-02-26, From 2022-01-01
2021-12-31-$187.09Mn/m2024-02-26, From 2021-01-01
2020-12-31-$108.16Mn/m2023-02-27, From 2020-01-01
2019-12-31-$47.66Mn/m2022-02-28, From 2019-01-01
2018-12-31-$41.79Mn/a2021-03-02, From 2018-01-01

Net Income at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedNet IncomeChange YoY
Revolution Medicines, Inc. (RVMD)2025-12-31-$1.13Bn/m
Vaxart, Inc. (VXRT)2025-12-31$16.33Mn/m
Amgen Inc (AMGN)2025-12-31$7.71B+88.5%
Repligen Corp (RGEN)2025-12-31$48.89Mn/m
Champions Oncology, Inc. (CSBR)2026-04-30-$1.18Mn/m
Bio-Techne Corp (TECH)2026-06-30$181.86M+147.8%
Biogen Inc. (BIIB)2025-12-31$1.29B-20.8%
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31-$63.53Mn/m
Gilead Sciences, Inc. (GILD)2025-12-31$8.51Bn/m

Compare RVMD, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗